Agios Pharmaceuticals, Inc.
38 Sidney Street
About Agios Pharmaceuticals, Inc.
>Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
August 7, 2007
Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su
CEO: David Schenkein
CMO (Medical): Chris Bowden
CSO (Scientific): Scott Biller
Please click here for Agios job opportunities.
Please click here for clinical trial information.
251 articles with Agios Pharmaceuticals, Inc.
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Celgene Vet Jackie Fouse Taking Over as CEO of Agios Pharmaceuticals; Companies Also Terminate Pr...
9/5/2018One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.
It’s a busy week on the U.S. Food and Drug Administration (FDA)’s calendar, although the agency got ahead of itself and approved three of the applications early. Here’s a look.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
7/20/2018Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a year.
New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today presented encouraging new data from a Phase 1 study evaluating ivosidenib (AG-120) or enasidenib (IDHIFA®; AG-221).
6/4/2018There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
With $87 Million in Hand, Beam Therapeutics Launches to Fight Disease with CRISPR Base Editing Te...
5/14/2018Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners.
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.
In addition, Agios highlighted select 2018 corporate milestones and data presentations for its clinical development programs.
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website.
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Jan. 24, 2018
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering.
Closing of the offering is expected to occur on or about January 23, 2018, subject to customary closing conditions.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value
The presentation will outline how Agios’ clinical and research programs have the potential to provide meaningful benefit to a large number of patients.
Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
Agios has requested priority review for the application, which, if granted, could result in a six-month review process.
12/21/2017A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.